Open AccessCalcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic Rickets
Author(s) -
Uri Alon,
Rachel Levy-Olomucki,
Wayne V. Moore,
Jason R. Stubbs,
Shiguang Liu,
L. Darryl Quarles
Publication year - 2008
Publication title -
clinical journal of the american society of nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.755
H-Index - 151
eISSN - 1555-905X
pISSN - 1555-9041
DOI - 10.2215/cjn.04981107
Subject(s) - cinacalcet , calcitriol , hypophosphatemia , endocrinology , medicine , parathyroid hormone , secondary hyperparathyroidism , phosphate , hyperparathyroidism , nephrocalcinosis , calcimimetic , fibroblast growth factor 23 , vitamin d and neurology , calcium , chemistry , kidney , biochemistry
The treatment for X-linked hypophosphatemia (XLH) with phosphate and calcitriol can be complicated by secondary hyperparathyroidism and nephrocalcinosis. Furthermore, vitamin D and phosphate stimulate FGF23 production, the pathogenic factor causing XLH. We investigated in XLH patients: 1) whether treatment with the calcimimetic agent, cinacalcet, will block the rise in parathyroid hormone (PTH) caused by phosphate administration; and 2) whether treatment with oral phosphate and calcitriol increases FGF23 levels.